国浩律师（深圳）事务所 关于 深圳华大基因股份有限公司 二〇二五年第二次临时股东会 之 法律意见书 广东省深圳市福田区深南大道 6008 号特区报业大厦 42、41、31DE、2403、2405，邮编：518034 42、41、31DE、2403、2405, Tequbaoye Building 6008 Shennan Avenue Shenzhen 518034, China 电话/Tel: +86 755 83515666 传真/Fax: +86 755 83515333 网址/Website: http://www.grandall.com.cn 二〇二五年十一月 1 深圳华大基因股份有限公司 2025 年第二次临时股东会法律意见书 国浩律师（深圳）事务所 关于深圳华大基因股份有限公司 二〇二五年第二次临时股东会之 法律意见书 编号：GLG/SZ/A2626/FY/2025-1476 号 致：深圳华大基因股份有限公司 国浩律师（深圳）事务所（以下简称本所）接受深圳华大基因股份有限公司 （以下简称公司、贵公司）委托，指派本所律师出席公司 2025 年第二次临时股 东会（以下简称本次股东会）。本所律师根据 ...

Core Viewpoint - The gene sequencing sector has shown a positive performance, with a 1.28% increase, ranking sixth among concept sectors, driven by significant gains in several stocks [1][2]. Group 1: Market Performance - As of November 12, the gene sequencing concept rose by 1.28%, with 45 stocks increasing in value, including notable gainers such as Kaineng Health (20% limit up), Nanjing Xinbai, and Zhongyuan Harmony, which also hit the limit up [1]. - The top gainers in the sector included Danna Biology (9.99%), Yihong Biological (6.71%), and Heyuan Biological (3.63%) [1]. - Conversely, the sector saw declines in stocks like Wavelength Optoelectronics, Gongjin Co., and Hanwang Technology, which fell by 3.16%, 2.40%, and 1.77% respectively [1]. Group 2: Capital Flow - The gene sequencing sector attracted a net inflow of 643 million yuan from major funds, with 31 stocks receiving net inflows, and 7 stocks exceeding 30 million yuan in net inflow [2]. - Zhongyuan Harmony led the net inflow with 220 million yuan, followed by Nanjing Xinbai and Kaineng Health with 176 million yuan and 174 million yuan respectively [2]. - The net inflow ratios for Nanjing Xinbai, Zhongyuan Harmony, and Jinyu Medical were 34.82%, 25.74%, and 18.18% respectively, indicating strong investor interest [3].

Core Viewpoint - The article discusses the significant impact of Guangzhou's policy on the development of the gene industry, highlighting the role of BGI Genomics in advancing gene testing accessibility and innovation in the sector [1][3]. Policy Impact - Guangzhou has prioritized the cell and gene industry as one of its six future industries, which is seen as a crucial step for the sector's growth [3]. - The policy elevates the industry from enterprise-led innovation to government-level design, providing a supportive framework for innovation and development [3][4]. - The implementation of this policy is viewed as a critical move for the localization of national macro policies [3]. Company Strategy - BGI Genomics is leveraging local policy advantages to expand its business, including establishing subsidiaries and developing domestic testing platforms [3][4]. - The company aims to make gene testing accessible to everyone by optimizing costs and enhancing technology [5][7]. - BGI Genomics plans to utilize Guangzhou's rich medical resources for clinical trials and the introduction of new diagnostic technologies [4][6]. Cost and Accessibility - High costs of gene testing have been a barrier to widespread adoption, but BGI Genomics is working to reduce these costs through self-sufficiency in technology and materials [5][6]. - Government initiatives, such as free prenatal screening programs, are seen as effective pathways to increase accessibility [5][6]. - The integration of gene testing into medical insurance is expected to broaden access, despite potential short-term revenue pressures for companies [6][7]. Data Assetization - The value of gene data is increasingly recognized, with a focus on data assetization while ensuring compliance and privacy [8]. - BGI Genomics is collaborating with Shenzhen Data Exchange to ensure strict data security measures [8]. - The company envisions using gene data to support the development of innovative drugs and early screening for rare diseases, aiming to reduce treatment costs [8]. Future Outlook - The gene industry is anticipated to experience new growth opportunities due to policy support, technological advancements, and the increasing value of data [8]. - BGI Genomics is committed to enhancing its competitiveness and contributing to societal progress through accessible gene testing [8].

Group 1 - The meeting held on November 4 focused on the role of private enterprises in advancing the digital economy and data industry, highlighting the strategic deployment from the 20th Central Committee of the Communist Party of China [1][2] - Private enterprises expressed optimism about the development prospects of the data industry, citing the ongoing reforms in the market-oriented allocation of data elements and the construction of a national integrated data market [1] - The construction of data infrastructure and high-quality data sets is seen as a new tool for enterprises to enhance their digital transformation and connectivity [1] Group 2 - Liu Liehong emphasized the significant advantages of private enterprises in promoting the data industry and artificial intelligence development, encouraging them to actively engage in data-related initiatives [2] - The National Data Bureau aims to create a favorable data policy environment for private enterprises by considering their feedback and continuously enhancing communication [2]

证券代码：300676 证券简称：华大基因 公告编号：2025-063 深圳华大基因股份有限公司 关于召开 2025 年第二次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《深圳华大基因股份有限公司章程》（以 下简称《公司章程》）的有关规定，经深圳华大基因股份有限公司（以下简称公 司）第四届董事会第七次会议审议通过，公司董事会决定于2025年11月12日（星 期三）召开公司2025年第二次临时股东会。《关于召开2025年第二次临时股东会 的 通 知 》（ 公 告 编 号 ： 2025-061 ） 已 于 2025 年 10 月 24 日 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn，下同）进行了公告。本次会议将采取现场表决与网 络投票相结合的方式召开，根据相关规定，现就本次会议有关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东会 7、会议出席对象： （1）截至2025年11月6日（星期四）下午收市时，在中国证券登记结算有限 责任公司深圳分公司 ...

Core Viewpoint - The meeting between the Prime Minister of Serbia and the CEO of BGI Group highlights the importance of collaboration in life sciences, agriculture, and education, with a focus on improving the quality of life for the Serbian population [1] Group 1 - The Serbian Prime Minister, Marcut, praised BGI Group's technological strength and its operations in Serbia [1] - Serbia is committed to advancing research and industrial development in the life sciences sector [1] - BGI Group expresses a strong willingness to contribute to major development projects in healthcare, education, and technology in Serbia [1]

Group 1 - On November 3, BGI Genomics conducted a block trade of 100,000 shares, with a total transaction value of 4.427 million yuan, accounting for 1.37% of the total trading volume for the day [1] - The transaction price was 44.27 yuan per share, which represents a 10% discount compared to the market closing price of 49.19 yuan [1] - The buyer of the block trade was an institutional investor, while the seller was Huafu Securities Co., Ltd. South China Branch [2]

Group 1 - The forum on financial empowerment of the private economy attracted significant attention, reflecting the rising interest in private enterprises following high-profile discussions and the introduction of the Private Economy Promotion Law [1][4] - Experts discussed the challenges faced by private enterprises, particularly the issue of "involution" driven by price wars, and emphasized the need for innovation as a solution [4][5] - The importance of creating a conducive policy environment for innovation was highlighted, with a focus on finding a "golden balance" in competition to stimulate innovation and prevent monopolistic practices [5][6] Group 2 - Financial support is crucial for the growth of private enterprises, with data showing that nearly two-thirds of A-share listed companies are private, and private enterprise loan growth has outpaced average loan growth by 1.1 percentage points over the past five years [7][8] - The role of venture capital and early-stage investments in helping private enterprises navigate challenges and foster innovation was emphasized, with suggestions for policies to encourage early and small investments in hard technology [8][9] - Recommendations were made for establishing a technology finance support system led by enterprises, including the use of long-term special government bonds to create patient capital for strategic emerging industries [8][9]

Core Insights - The article highlights the recognition of Xu Qian, the Vice President and General Counsel of BGI Genomics, as one of the "Top 15 General Counsels in China" by Asian Legal Business, reflecting her outstanding contributions in legal exploration, technological innovation, and global compliance [1][4]. Group 1: Recognition and Awards - The "Top 15 General Counsels in China" list has been published for ten consecutive years, aiming to identify outstanding general counsels who demonstrate foresight, leadership, and significant influence in complex environments [4]. - Xu Qian's inclusion in the list is a testament to her exceptional legal skills and strategic understanding of business, which have redefined the role of general counsel and expanded its value boundaries [4]. Group 2: AI and Legal Compliance - BGI Genomics is integrating AI technology into its research platforms, data analysis, and clinical applications, enhancing diagnostic efficiency while ensuring data sovereignty and compliance [5]. - The company has launched innovative products, such as the "Hereditary Tumor Variation Knowledge Base," addressing gaps in domestic tumor precision diagnosis data products, supported by a robust legal compliance team [5]. Group 3: Globalization and Compliance Strategy - BGI Genomics is advancing its globalization strategy by establishing precision medicine laboratories and joint ventures in key overseas markets, promoting Chinese technology and standards internationally [6]. - Under Xu Qian's leadership, the company has developed an international compliance system, becoming the first in China to obtain ISO37301 compliance management certification, which enhances its global strategy and sets a positive example for industry compliance standards [6]. Group 4: Role Evolution of Legal Team - Xu Qian has transformed the legal team's role from risk managers to drivers of technological innovation and global strategy, emphasizing the critical value of legal expertise in the high-quality development of the life sciences sector [7]. - The legal team is expected to continue its focus on cutting-edge legal issues, providing strong legal support for corporate innovation and industry compliance upgrades [7].

Core Insights - The company reported that as of the end of Q3 this year, the total sample volume for its colorectal cancer screening project exceeded 400,000, generating nearly 100 million yuan in revenue [1] Group 1: Business Performance - The colorectal cancer screening project has shown significant growth with over 400,000 samples processed [1] - Revenue from this project is approaching 100 million yuan, indicating strong market demand [1] Group 2: Strategic Direction - The company plans to accelerate its transformation from a "testing service" model to a comprehensive model that includes "products + services + data" [1] - This strategic shift aims to establish a dual-driven model targeting both consumer (C-end) and business (B-end) markets [1]